The Center for Business Intelligence is hosting "Intellectual Asset Management Strategies" in Baltimore, MD on January 20 - 21, 2009. The conference will focus on Legal, Intellectual Property, Regulatory, Patents, Portfolio, Licensing and Lifecycle issues facing the pharmaceutical and biotechnology industries.
The economy is changing, regulations are increasing and pharmaceutical companies are under more scrutiny worldwide than ever before. CBI’s Summit on Intellectual Asset Management Strategies brings together leaders from the pharmaceutical industry to discuss these changes and share strategies for success in this market. Hear the latest legal perspectives from leading industry executives to gain a competitive edge.
Faculty
- David E. Korn, Assistant General Counsel, PhRMA
- Hans Sauer, Ph.D., J.D., Associate General Counsel for Intellectual Property, Biotechnology Industry Organization (BIO)
- George C. Elliott, Ph.D., Group Director, Patent and Trademark Office
- Jeffrey Brennan, Partner, Dechert LLP
- Geoff Levitt, Vice President and Chief Regulatory Counsel, Wyeth
- Len S. Smith, J.D., Senior Intellectual Property Counsel, Novo Nordisk
In addition, the program will include an FTC address titled, "Antitrust Law and LCM — The FTC’s View on Risks and Regulations" led by Mark J. Woodward, Senior Attorney, Federal Trade Commission.
More details and registration are available here.
Comments